Active	Status	Sponsor type	Region	Phase	Filter
55 Active 38 Inactive 93 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Giordano, Carla
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	Active, not recruiting	4	780	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Antihyperglycemic medication	Eli Lilly and Company	Type 2 Diabetes	10/25	11/27
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
Badalamenti, Giuseppe
TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)	Recruiting	3	128	Europe, Canada, US, RoW	Emactuzumab, Placebo	SynOx Therapeutics Limited	TGCT	04/26	09/27
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
ERASING, NCT03840772 / 2018-004571-12: Eribulin in Advanced Solitary Fibrous Tumor	Completed	2	16	Europe	Eribulin, Intervention under investigation	Italian Sarcoma Group, Eisai Inc.	Solitary Fibrous Tumor	09/24	09/24
ACCeSs, NCT04274023 / 2016-004368-21: Study on TSR-042 in Advanced Clear Cell Sarcoma	Terminated	2	3	Europe	TSR-042	Italian Sarcoma Group, GlaxoSmithKline	Sarcoma, Clear Cell	01/24	01/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma	Recruiting	2	16	Europe	Trabectedin	Italian Sarcoma Group, PharmaMar	Mesenchymal Chondrosarcoma	08/25	12/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.	Completed	2	130	Europe	Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm	Italian Sarcoma Group, PharmaMar, AstraZeneca	Advanced Soft Tissue Sarcoma	11/24	11/24
Tuttolomondo, Antonino
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease	Active, not recruiting	3	122	Europe, Canada, Japan, US, RoW	Venglustat (GZ402671), Placebo	Sanofi, Sanofi-Aventis Recherche & Développement	Fabry Disease	12/25	12/26
Agrusa, Antonino
No trials found
Novo, Giuseppina
No trials found
Chiantera, Vito
No trials found
Donna, Mariano Catello Di
No trials found
Buono, Giuseppe Di
No trials found
Giunta, Rocco
No trials found
Panzarella, Vera
No trials found